Related Experiment Video

Updated: Jun 13, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Rapamycin sensitizes Akt inhibition in malignant human breast epithelial cells

Jie Zheng1, Alice Hudder, Kim Zukowski

  • 1Institute of Environmental Health Sciences, Wayne State University, Detroit, MI 48201, USA.

Cancer Letters
|April 27, 2010
PubMed

Insights

Combined inhibition of Akt and mTOR with rapamycin and A-443654 shows promise for cancer therapy. This approach effectively altered cell morphology, halted proliferation, and induced apoptosis, particularly in tumor cells.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • The Akt and mTOR signaling pathways are crucial in cancer development and are recognized as key therapeutic targets.
  • Understanding the combined effects of inhibiting these pathways is essential for developing effective cancer treatments.

Purpose of the Study:

  • To investigate the synergistic effects of concurrently inhibiting Akt and mTOR using A-443654 and rapamycin, respectively.
  • To evaluate the impact of this combined inhibition on cell morphology, proliferation, cell cycle, and apoptosis in benign and malignant human breast epithelial cells.

Main Methods:

  • Utilized benign MCF10A and malignant MCF10CA1a human breast epithelial cell lines.
  • Administered combined treatment with rapamycin (mTOR inhibitor) and A-443654 (Akt inhibitor).
  • Assessed changes in cell morphology, proliferation, cell cycle distribution, apoptosis, and protein levels (p53, p15(INK4B), Bcl-2, Bad).

Main Results:

  • Combined inhibition resulted in significant morphological changes and G2/M cell cycle arrest, inhibiting proliferation.
  • Apoptosis was induced earlier and at lower concentrations of A-443654 in MCF10CA1a tumor cells compared to MCF10A benign cells.
  • Treatment increased p53 and p15(INK4B) levels, decreased Bcl-2, and increased Bad levels in tumor cells.

Conclusions:

  • Concurrent inhibition of Akt and mTOR pathways demonstrates potential therapeutic benefits in cancer treatment.
  • The combined approach may offer an improved safety margin due to differential effects on tumor versus benign cells.
  • Further research into combined Akt and mTOR inhibition is warranted for cancer therapy development.

More Related Videos

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...